These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 26664121)

  • 1. Profile of brivaracetam and its potential in the treatment of epilepsy.
    Ferlazzo E; Russo E; Mumoli L; Sueri C; Gasparini S; Palleria C; Labate A; Gambardella A; De Sarro G; Aguglia U
    Neuropsychiatr Dis Treat; 2015; 11():2967-73. PubMed ID: 26664121
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Brivaracetam: review of its pharmacology and potential use as adjunctive therapy in patients with partial onset seizures.
    Mumoli L; Palleria C; Gasparini S; Citraro R; Labate A; Ferlazzo E; Gambardella A; De Sarro G; Russo E
    Drug Des Devel Ther; 2015; 9():5719-25. PubMed ID: 26543353
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brivaracetam: a novel antiepileptic drug for focal-onset seizures.
    Stephen LJ; Brodie MJ
    Ther Adv Neurol Disord; 2018; 11():1756285617742081. PubMed ID: 29399049
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Brivaracetam in the treatment of epilepsy: a review of clinical trial data.
    Feyissa AM
    Neuropsychiatr Dis Treat; 2019; 15():2587-2600. PubMed ID: 31571877
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Brivaracetam as adjunctive treatment for uncontrolled partial epilepsy in adults: a phase III randomized, double-blind, placebo-controlled trial.
    Biton V; Berkovic SF; Abou-Khalil B; Sperling MR; Johnson ME; Lu S
    Epilepsia; 2014 Jan; 55(1):57-66. PubMed ID: 24446953
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emerging drugs for partial-onset epilepsy: a review of brivaracetam.
    Gao L; Li S
    Ther Clin Risk Manag; 2016; 12():719-34. PubMed ID: 27217762
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and tolerability of adjunctive brivaracetam in adults with uncontrolled partial-onset seizures: a phase IIb, randomized, controlled trial.
    Van Paesschen W; Hirsch E; Johnson M; Falter U; von Rosenstiel P
    Epilepsia; 2013 Jan; 54(1):89-97. PubMed ID: 22813235
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjunctive brivaracetam for uncontrolled focal and generalized epilepsies: results of a phase III, double-blind, randomized, placebo-controlled, flexible-dose trial.
    Kwan P; Trinka E; Van Paesschen W; Rektor I; Johnson ME; Lu S
    Epilepsia; 2014 Jan; 55(1):38-46. PubMed ID: 24116853
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjunctive brivaracetam in adults with uncontrolled focal epilepsy: results from a double-blind, randomized, placebo-controlled trial.
    Ryvlin P; Werhahn KJ; Blaszczyk B; Johnson ME; Lu S
    Epilepsia; 2014 Jan; 55(1):47-56. PubMed ID: 24256083
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A single-center, open-label positron emission tomography study to evaluate brivaracetam and levetiracetam synaptic vesicle glycoprotein 2A binding in healthy volunteers.
    Finnema SJ; Rossano S; Naganawa M; Henry S; Gao H; Pracitto R; Maguire RP; Mercier J; Kervyn S; Nicolas JM; Klitgaard H; DeBruyn S; Otoul C; Martin P; Muglia P; Matuskey D; Nabulsi NB; Huang Y; Kaminski RM; Hannestad J; Stockis A; Carson RE
    Epilepsia; 2019 May; 60(5):958-967. PubMed ID: 30924924
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Brivaracetam: Rationale for discovery and preclinical profile of a selective SV2A ligand for epilepsy treatment.
    Klitgaard H; Matagne A; Nicolas JM; Gillard M; Lamberty Y; De Ryck M; Kaminski RM; Leclercq K; Niespodziany I; Wolff C; Wood M; Hannestad J; Kervyn S; Kenda B
    Epilepsia; 2016 Apr; 57(4):538-48. PubMed ID: 26920914
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and tolerability of adjunctive brivaracetam in patients with prior antiepileptic drug exposure: A post-hoc study.
    Asadi-Pooya AA; Sperling MR; Chung S; Klein P; Diaz A; Elmoufti S; Schiemann J; Whitesides J
    Epilepsy Res; 2017 Mar; 131():70-75. PubMed ID: 28279891
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A review of the pharmacology and clinical efficacy of brivaracetam.
    Klein P; Diaz A; Gasalla T; Whitesides J
    Clin Pharmacol; 2018; 10():1-22. PubMed ID: 29403319
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Postmarketing experience with brivaracetam in the treatment of epilepsies: A multicenter cohort study from Germany.
    Steinig I; von Podewils F; Möddel G; Bauer S; Klein KM; Paule E; Reif PS; Willems LM; Zöllner JP; Kunz R; Runge U; Kurlemann G; Schubert-Bast S; Rosenow F; Strzelczyk A
    Epilepsia; 2017 Jul; 58(7):1208-1216. PubMed ID: 28480518
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized, double-blind, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy and safety of adjunctive brivaracetam in adult patients with uncontrolled partial-onset seizures.
    Klein P; Schiemann J; Sperling MR; Whitesides J; Liang W; Stalvey T; Brandt C; Kwan P
    Epilepsia; 2015 Dec; 56(12):1890-8. PubMed ID: 26471380
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New developments in the management of partial-onset epilepsy: role of brivaracetam.
    Coppola G; Iapadre G; Operto FF; Verrotti A
    Drug Des Devel Ther; 2017; 11():643-657. PubMed ID: 28293101
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Brivaracetam efficacy and safety in focal epilepsy.
    Makke Y; Abou-Khalil B
    Expert Rev Neurother; 2019 Oct; 19(10):955-964. PubMed ID: 31195850
    [No Abstract]   [Full Text] [Related]  

  • 18. Favorable adverse effect profile of brivaracetam vs levetiracetam in a preclinical model.
    Sanon NT; Gagné J; Wolf DC; Aboulamer S; Bosoi CM; Simard A; Messiet E; Desgent S; Carmant L
    Epilepsy Behav; 2018 Feb; 79():117-125. PubMed ID: 29287214
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Brivaracetam augments short-term depression and slows vesicle recycling.
    Yang X; Bognar J; He T; Mohammed M; Niespodziany I; Wolff C; Esguerra M; Rothman SM; Dubinsky JM
    Epilepsia; 2015 Dec; 56(12):1899-909. PubMed ID: 26515103
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Brivaracetam, a selective high-affinity synaptic vesicle protein 2A (SV2A) ligand with preclinical evidence of high brain permeability and fast onset of action.
    Nicolas JM; Hannestad J; Holden D; Kervyn S; Nabulsi N; Tytgat D; Huang Y; Chanteux H; Staelens L; Matagne A; Mathy FX; Mercier J; Stockis A; Carson RE; Klitgaard H
    Epilepsia; 2016 Feb; 57(2):201-9. PubMed ID: 26663401
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.